Skip to main content

Drug Interactions between entacapone and Therobec Plus

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

multivitamin with minerals entacapone

Applies to: Therobec Plus (multivitamin with minerals) and entacapone

ADJUST DOSING INTERVAL: The oral bioavailability of entacapone and iron salts may be decreased during concurrent administration. The proposed mechanism is chelation of iron by entacapone, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract. Entacapone has been shown to be a chelator of iron. The impact of entacapone on the body's iron stores is unknown, but in clinical trials, a tendency towards decreasing serum iron concentrations was reported. In one controlled study, serum ferritin levels (a marker of iron deficiency and subclinical anemia) were not altered with entacapone compared to placebo, and there was no difference in frequency of anemia or decreased hemoglobin levels. However, slight decreases in hemoglobin, erythrocyte count, and hematocrit have been reported during entacapone treatment. After 6 months of entacapone therapy, a clinically significant decrease in hemoglobin has been observed in 1.5% of patients.

MANAGEMENT: Patients receiving entacapone concomitantly with iron-containing products should be advised to separate the times of administration by 2 to 3 hours.

References

  1. (2001) "Product Information. Comtan (entacapone)." Novartis Pharmaceuticals

Switch to consumer interaction data

Drug and food interactions

Moderate

entacapone food

Applies to: entacapone

GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.

MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.

References

  1. Warrington SJ, Ankier SI, Turner P (1986) "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology, 15, p. 31-7
  2. Gilman AG, eds., Nies AS, Rall TW, Taylor P (1990) "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.
  3. (2012) "Product Information. Fycompa (perampanel)." Eisai Inc
  4. (2015) "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc
View all 4 references

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.